Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 12/2006

01-12-2006 | Original Article

An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting

Based on the results of the SOTI and TROPOS trials

Authors: F. Borgström, B. Jönsson, O. Ström, J. A. Kanis

Published in: Osteoporosis International | Issue 12/2006

Login to get access

Abstract

Introduction

Strontium ranelate is a new therapy for the treatment and prevention of osteoporosis that has been shown in two phase III clinical trials (the Spinal Osteoporosis Therapeutic Intervention [SOTI] and the Treatment Of Peripheral OSteoporosis Study [TROPOS] trials) to reduce the risk of osteoporotic fractures at the vertebral, non-vertebral and hip level in postmenopausal women. The aim of this study was to estimate the potential cost-effectiveness of strontium ranelate in the treatment of osteoporosis in postmenopausal Swedish patients.

Methods

A Markov cohort model was adapted to fit patients corresponding to the patients in the SOTI and TROPOS clinical trials. The model was populated with Swedish cost and epidemiological data. In the base case, the cost-effectiveness was estimated for 69-year old women with low bone mineral density (BMD) and prevalent vertebral fractures (SOTI) and for 77-year old women with low BMD (TROPOS). The cost-effectiveness analysis had a societal perspective.

Results

In the base case analysis, the cost per quality-adjusted life years (QALY) gained of strontium ranelate patients compared to no treatment patients was estimated at SEK 472,586 and SEK 259,643, including costs in added life years, based on the SOTI and the TROPOS trials, respectively. Excluding cost in added life years, the cost per QALY gained was estimated at SEK 336,420 (SOTI) and SEK 165,680 (TROPOS). In subgroup analyses, in patients 74 years and older with a T-score lower than −2.4 and patients older than 80 years of age, strontium ranelate was found to be cost saving compared to no treatment.

Conclusions

The results in the base case analyses and the sensitivity analyses of this study indicate that, compared to no treatment, strontium ranelate is cost-effective in the treatment of postmenopausal women with low BMD.
Literature
1.
Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468PubMedCrossRef
2.
Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822PubMedCrossRef
3.
Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21(5):305–314PubMedCrossRef
4.
Borgstrom F, Zethraeus N (2003) Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective. Lakartidningen 100(1–2):36–40PubMed
5.
Borgstrom F, Johnell O, Jonsson B, Zethraeus N, Sen SS (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34(6):1064–1071PubMedCrossRef
6.
Jonsson L, Borgstrom F, Zethraeus N (2003) Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial. Ugeskr Laeger 165(43):4112–4116PubMed
7.
Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15(11):862–871PubMedCrossRef
8.
Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8(5):468–489PubMedCrossRef
9.
Seeman E, Vellas B, Meunier P, Roux C, Adami S, Aquino J, Semler J, Graham J, Sorensen O (2005) Vertebral and nonvertebral antifracture efficacy of strontium ranelate in very elderly women with osteoporosis. Osteoporos Int 16(Suppl 3):OC21:S6
10.
11.
Reginster JY, Meunier PJ (2003) Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int 14(Suppl 3):S56–S65PubMed
12.
Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C (2002) Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 13(12):925–931PubMedCrossRef
13.
Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87(5):2060–2066PubMedCrossRef
14.
Jonsson B (1998) Targeting high-risk populations. Osteoporos Int 8(Suppl 1):S13–S16PubMed
15.
Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38PubMed
16.
Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 22(17):1153–1165PubMedCrossRef
17.
Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16(1):15–25PubMedCrossRef
18.
Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, de Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11(8):669–674PubMedCrossRef
19.
Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417–427PubMedCrossRef
20.
Melton LJ 3rd, Crowson CS, O’Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9(1):29–37PubMedCrossRef
21.
Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11(2):120–127PubMedCrossRef
22.
de Laet CE, van Hout BA, Burger H, Hofman A, Pols HA (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. Br Med J 315(7102):221–225
23.
Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312(7041):1254–1259
24.
Kanis JA, Johnell O, de Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382PubMedCrossRef
25.
Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721–739PubMedCrossRef
26.
27.
Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11(7):556–561PubMedCrossRef
28.
Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156):878–882PubMedCrossRef
29.
Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137(9):1001–1005PubMed
30.
Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J, McCloskey E (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18(7):1254–1260PubMedCrossRef
31.
Kanis JA, Oden A, Johnell O, de Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108–112PubMedCrossRef
32.
Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8(6):599–603PubMedCrossRef
33.
Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, de Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38–42PubMedCrossRef
34.
Poor G, Atkinson EJ, O’Fallon WM, Melton LJ 3rd (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop Oct(319):260–265
35.
Kanis J, Johnell O, Oden A, de Laet C, Jonsson B, Oglesby A (2002) Excess mortality after vertebral fracture. WHO Collaborating Centre for Metabolic Bone Diseases, Sheffield, UK
36.
Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105(6):443–446PubMedCrossRef
37.
Kanis JA, Oden A, Johnell O, de Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32(5):468–473PubMedCrossRef
38.
Läkemedelsförmånsnämndens allmänna råd (2003) Stockholm
39.
Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68(1):13–17PubMedCrossRef
40.
Zethraeus N, Borgström F, Johnell O, Kanis J, Jönsson B (2002) Costs and quality of life associated with osteoporosis related fractures—results from a Swedish survey. Working Paper Series in Economics and Finance, no 512, Stockholm School of Economics, Stockholm, Sweden
41.
42.
de Laet CE, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 10(1):66–72PubMedCrossRef
43.
Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16(1):33–64PubMedCrossRef
44.
Ekman M, Zethraeus N, Dahlstrom U, Hoglund C (2002) Cost-effectiveness of bisoprolol in chronic heart failure. Lakartidningen 99(7):646–650PubMed
45.
46.
Priser för södra sjukvårdsregionen–Vårdtjänster per klinik (2003) Universitetssjukhuset i Lund
47.
Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10(7):621–635PubMedCrossRef
48.
Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316(7133):736–741
49.
Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, de Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15(1):20–26PubMedCrossRef
50.
Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15(7):1384–1392PubMedCrossRef
51.
Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13(10):768–776PubMedCrossRef
52.
Tidermark J, Zethraeus N, Svensson O, Tornkvist H, Ponzer S (2002) Quality of life related to fracture displacement among elderly patients with femoral neck fractures treated with internal fixation. J Orthop Trauma 16(1):34–38PubMedCrossRef
53.
(2002) Översyn av samhällsekonomiska metoder och kalkylvården på transportområdet—ASEK review of cost benefit calculation. Methods and valuations in the transport sector. SIKA Rapport 4
54.
Persson U, Hjelmgren J (2003) Health services need knowledge of how the public values health. Lakartidningen 100(43):3436–3437PubMed
55.
Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jönsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden—an economic evaluation based on the MORE study. Pharmacoeconomics 22(17):1153–1165PubMedCrossRef
56.
(2003) PROTELOS—prevention and treatment of postmenopausal osteoporosis. Clinical Investigators’ brochure no 7
57.
Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD (1993) Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int 3(3):120–126PubMedCrossRef
Metadata
Title
An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting
Based on the results of the SOTI and TROPOS trials
Authors
F. Borgström
B. Jönsson
O. Ström
J. A. Kanis
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 12/2006
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-006-0193-z

Other articles of this Issue 12/2006

Osteoporosis International 12/2006 Go to the issue

Original Article

Bone density and bone area in Canadian Aboriginal women: the First Nations Bone Health Study

Original Article

Vertebral height restoration in osteoporotic compression fractures: kyphoplasty balloon tamp is superior to postural correction alone

Letter

Osteoprotegerin and bone mineral density in hemodialysis patients: reply to letter by Ulivieri et al.

Review

Sacral insufficiency fractures: current concepts of management

Original Article

Effects of a combined alendronate and calcitriol agent (Maxmarvil®) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study

Original Article

Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study